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Vitamin D and secreted Klotho:
a long-awaited panacea for
vascular calcification?
Hirotaka Komaba1 and Masafumi Fukagawa1
Chronic kidney disease (CKD) is characterized by accelerated vascular
calcification, which may in part be caused by deficiency of the anti-
aging factor Klotho. Lau et al. demonstrate that administration of active
vitamin D and its analog decreases aortic calcification in association
with increases in two potent calcification inhibitors—the secreted form
of Klotho and vascular osteopontin. These data might provide a new
perspective on the association of active vitamin D with improved
survival in patients with CKD.
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Vascular calcification is one of the
major complications of chronic kidney
disease (CKD) and contributes to an
increased risk of cardiovascular mor-
bidity and mortality in this population.
Emerging evidence suggests that vascu-
lar calcification is not just a passive
process of mineral precipitation but a
pathobiological process that shares
many features with skeletal osteogenesis
and involves various calcification in-
ducers and inhibitors.1 Recently, epide-
miological studies of CKD patients
demonstrated a significant survival
benefit associated with the use of
active vitamin D—the mainstream
therapy for secondary hyperparathyro-
idism—independently of the tradi-
tional effects on mineral metabolism.2
A plausible explanation for these
findings is provided by experimental
studies showing several nonclassical
actions of vitamin D, including effects
on the immune and inflammatory
system, the renin–angiotensin system,
and cell growth and differentiation. In
addition, recent data suggest that a
physiological dose of active vitamin D
may have protective effects against
vascular calcification, although a supra-
physiological dose of active vitamin D
induces massive vascular calcification in
experimental uremia.3
Klotho, originally identified as an
anti-aging factor, is a 130-kDa single-
pass transmembrane protein that is
predominantly expressed in the kidney,
parathyroid gland, and choroid plexus.4
Klotho functions as an obligate cofactor
for fibroblast growth factor-23 (FGF23)
and mediates the effects of FGF23 to
induce urinary phosphate excretion,
suppress renal production of 1,25-
dihydroxyvitamin D, and inhibit
synthesis and secretion of parathyroid
hormone.5 The extracellular domain of
Klotho can be secreted into blood,
urine, and cerebrospinal fluid and
functions as a humoral factor. Recent
experimental data showed that secreted
Klotho enhances calcium reabsorption
in the distal tubule, promotes phos-
phaturia in the proximal tubule,6 and
inhibits phosphate uptake by vascular
smooth muscle cells.7 Interestingly,
systemic expression of Klotho is
decreased in humans and animals
with CKD, and it is suggested that
Klotho deficiency may contribute to
development of vascular calcification as
well as resistance to FGF23 in the
kidney and parathyroid gland in CKD.5
Whether the putative protective ef-
fect of active vitamin D against vascular
calcification is mediated by secreted
Klotho or other calcification-related
factors is the subject of the study by
Lau et al.8 (this issue). Using a uremic
mouse model of extensive arterial
medial calcification generated by
partial renal ablation and a high-
phosphate (1.5%) diet on the calci-
fication-prone DBA/2J background, the
investigators examined the effect of
calcitriol or its analog paricalcitol on
vascular calcification. They revealed that
both types of active vitamin D, in doses
equivalent to those given to patients
with CKD, increases serum and urinary
levels of secreted Klotho and expression
of the calcification inhibitor osteopontin
in aortic medial cells, and ameliorates
aortic medial calcification (Figure 1).
These results suggest that pharmacolo-
gical doses of active vitamin D may
have beneficial effects on vascular calci-
fication by increasing secreted Klotho
and arterial medial osteopontin in the
setting of CKD.
Although the results of the study by
Lau et al.8 might provide a new pers-
pective on the association of active
vitamin D with improved survival in
patients with CKD,2 their data should
be interpreted with caution. First, the
administration of calcitriol or paricalci-
tol resulted in paradoxical reductions in
serum phosphate and FGF23 and no
effects on serum calcium and parath-
yroid hormone. Perhaps these findings
may in part be explained by the high
dietary phosphate content used in the
study, which might have overcome the
inhibitory effect of active vitamin D on
parathyroid hormone secretion and the
potent phosphaturic action of secreted
Klotho that was increased by active
vitamin D. As the investigators acknow-
ledge, this experimental model might
be reasonable for examining the effect
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of active vitamin D on secreted Klotho
and vascular calcification indepen-
dently of changes in serum calcium
and parathyroid hormone. However,
since the observed changes are largely
different from those in patients with
CKD, additional studies are required to
determine whether the results of this
animal study are true of patients with
CKD in the real world.
Second, it remains unclear how the
secreted form of Klotho in blood and
urine was increased by active vitamin
D. To elucidate this mechanism, the
investigators analyzed systemic expres-
sion of Klotho in detail. However, they
found that Klotho expression in the
kidney was not upregulated by active
vitamin D in their experimental model,
in contrast to previous studies.9
Similarly, no upregulation of Klotho
expression was observed in other
organs, including the parathyroid, in
mice treated with active vitamin D.
These data raise the possibility that the
increased secreted Klotho following
administration of active vitamin D
may be caused by accelerated shedding
of Klotho without changes in
membrane-bound Klotho expression,
although the source of secreted Klotho
and the mechanism of regulation of
Klotho cleavage are largely unknown. A
recent study of hemodialysis patients
has shown that treatment with
cinacalcet hydrochloride resulted in
only small and transient reductions in
serum secreted Klotho despite signi-
ficant alterations in mineral and bone
metabolism.10 Future studies should
investigate the mechanism by which
shedding of membrane-bound Klotho
is regulated and the involvement of
active vitamin D in this process.
Third, the study by Lau et al.8 does
not provide evidence that increased
secreted Klotho actually contributed
to the protective effects of active
vitamin D against vascular calcifica-
tion in their model. Recent in vitro
studies demonstrated direct effects of
secreted Klotho protein on vascular
smooth muscle cell calcification
through suppression of sodium-depen-
dent phosphate transport into cells,7
but the in vivo significance of these
effects remains unknown. Because
secreted Klotho functions as a phos-
phaturic hormone independently of the
effect of FGF23,6 the observed amelio-
ration of vascular calcification may be
attributable to the phosphaturic effect
of secreted Klotho. Lau et al.8 also
demonstrated upregulated expression
of osteopontin, a potent local inhibi-
tor of vascular calcification, following
administration of active vitamin D.
Again, however, it remains to be deter-
mined whether the upregulation of
osteopontin by active vitamin D contri-
buted to the improvement of vascular
calcification in this mouse model.
Finally, it is important to point out
that the protective or detrimental effect
of active vitamin D on vascular calci-
fication has been a controversial issue,
presumably because of the differences
in the experimental model or the dose
or type of active vitamin D used.3 This
suggests the possibility of a therapeutic
window for active vitamin D to exert
protective actions against vascular
calcification, which may vary accord-
ing to the type of active vitamin D. In
this regard, additional studies are
needed to determine whether the
effects of active vitamin D on secreted
Klotho and arterial medial osteopontin
differ according to the dose over a
much wider range than examined in the
study by Lau et al.8 In addition, it
would be important to investigate whe-
ther supplementation of native vitamin
D to correct vitamin D deficiency,
which occurs commonly in patients
with CKD, results in modulation of
secreted Klotho and other calcification-
related factors and whether these effects
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Figure 1 | Proposed mechanisms of inhibition of vascular calcification by active
vitamin D. Active vitamin D inhibits vascular calcification by two possible pathways:
(1) increasing secreted Klotho, which in turn enhances phosphaturia and directly inhibits
phosphate uptake by vascular smooth muscle cells; and (2) increasing expression of the
calcification inhibitor osteopontin in aortic medial cells.
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translate into protective effects against
vascular calcification.
Despite these caveats, the study by
Lau et al.8 is important, as it adds a new
dimension to the beneficial effects of
active vitamin D on the vasculature in
patients with CKD—who are in a state
of Klotho deficiency.7 The results of this
study highlight the need to determine
whether an optimal dose of active
vitamin D is a panacea for vascular
calcification in patients with CKD and, if
so, whether secreted Klotho is involved
in this beneficial effect of active vitamin
D. Clearly, there is still much to learn
about the role of vitamin D and secreted
Klotho in the pathogenesis of vascular
calcification in CKD, and much more
work is needed to translate the findings
of this study into clinical practice in
patients with CKD.
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Autophagy protects proximal
tubular cells from injury and
apoptosis
Gur P. Kaushal1,2,3
Autophagy is upregulated during ischemia–reperfusion (IR)-induced
and cisplatin-induced acute kidney injury (AKI). Proximal tubule-specific
Atg7 knockout mice exhibited increased renal injury compared with
wild-type mice following cisplatin- and IR-induced AKI. Inhibition of
autophagy by chloroquine aggravated AKI, whereas upregulation of
autophagy by rapamycin recovered lost renal function and histology,
further indicating a protective role of autophagy in AKI. These findings
reported by Jiang et al. will provide stimulus to further examine the
role and mechanism of the enhancement of autophagy in AKI.
Kidney International (2012) 82, 1250–1253. doi:10.1038/ki.2012.337
Autophagy is a catabolic process of
degradation of long-lived proteins,
cellular macromolecules, and intracel-
lular organelles through the lysosomal
hydrolases. In this process, a double-
membrane structure known as an
autophagosome sequesters and delivers
cytoplasmic contents to the lysosome
for degradation. Free amino acids and
fatty acids generated on degradation of
cellular components are recycled to
synthesize new proteins and bioener-
getic supplies of the cell. Thus, under
normal physiological conditions, basal
autophagy plays a homeostatic role that
maintains cellular homeostasis and
quality control. Autophagy is induced
in response to stress conditions includ-
ing cell starvation, growth factor depri-
vation, hypoxia, and oxidant injury.
Under stress conditions, autophagy
induction is generally considered to
play an adaptive role that ensures cell
survival. The molecular machinery in-
volved in autophagosome formation is
composed of evolutionarily conserved
Atg-related proteins originally identi-
fied in yeast.1 The formation of an
autophagosome is initiated by several
autophagic protein complexes, includ-
ing the unc-51-like kinase 1 or 2
(ULK1 or ULK2) complex, the class
III phosphatidylinositol 3-kinase com-
plex, Atg12–Atg5–Atg16 conjugation,
and lipidation of microtubule-asso-
ciated protein 1 light chain 3 (LC3)
with phosphatidylethanolamine to form
LC3-II1 (Figure 1). The elongation and
expansion steps in autophagosome for-
mation involve two ubiquitin-like pro-
teins, Atg12 and Atg8/LC3 (Figure 1).
The conjugation of Atg12 to Atg5 is
catalyzed by Atg7 and Atg10 (E1- and
E2-like enzymes, respectively) to form
covalently linked Atg12–Atg5. Follow-
ing formation of the Atg12–Atg5
conjugate, Atg16L non-covalently asso-
ciates with this conjugate to produce
the Atg12–Atg5–Atg16 multimeric com-
plex.1 At present, there is great interest
in studying autophagy under various
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